Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Working Capital Changes (2020 - 2025)

Insight Molecular Diagnostics' Other Working Capital Changes history spans 6 years, with the latest figure at $189000.0 for Q3 2025.

  • For Q3 2025, Other Working Capital Changes fell 37.62% year-over-year to $189000.0; the TTM value through Sep 2025 reached -$520000.0, down 158.36%, while the annual FY2024 figure was -$291000.0, 171.96% down from the prior year.
  • Other Working Capital Changes for Q3 2025 was $189000.0 at Insight Molecular Diagnostics, up from -$35000.0 in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $1.1 million in Q1 2021 and bottomed at -$1.0 million in Q4 2021.
  • The 5-year median for Other Working Capital Changes is -$30000.0 (2025), against an average of -$32473.7.
  • The largest annual shift saw Other Working Capital Changes tumbled 606.92% in 2021 before it soared 1245.0% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.0 million in 2021, then skyrocketed by 103.94% to $40000.0 in 2022, then skyrocketed by 1245.0% to $538000.0 in 2023, then crashed by 219.7% to -$644000.0 in 2024, then soared by 129.35% to $189000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Other Working Capital Changes are $189000.0 (Q3 2025), -$35000.0 (Q2 2025), and -$30000.0 (Q1 2025).